Nursing care
Laxatives: what to check before you give it
Written and reviewed by Dana Whitfield, RN, MSN · 5 min read · Updated September 2026
Short answer
Laxatives relieve or prevent constipation by increasing stool bulk, softening stool, stimulating peristalsis, or drawing water into the bowel, depending on class. The class dictates the nursing check: a stool softener like docusate does not treat pain-related immobility of the bowel the way a stimulant does, so opioid patients typically need both together, not one or the other.
Mechanism, simply
Four classes, four different jobs. Bulk-forming agents such as psyllium absorb water and swell, increasing stool mass and stretching the bowel wall to trigger the urge to go. Osmotic agents such as polyethylene glycol and lactulose pull water into the colon by osmosis, softening stool and increasing volume. Stimulant laxatives such as senna and bisacodyl act directly on the intestinal mucosa, increasing motility and peristalsis. Stool softeners such as docusate are surfactants: they let water and fat penetrate the stool itself, easing its passage without touching motility.
That last distinction is the one to hold onto. Docusate makes stool easier to pass through a bowel that is already moving. It does nothing to make a sluggish bowel move. If motility is the problem, only a stimulant or osmotic agent addresses it.
Indications you will see on the ward
Postoperative constipation from anaesthesia and reduced mobility, opioid-induced constipation, straining to avoid raising intracranial or intraocular pressure or after an MI, bowel prep before colonoscopy, and simple functional constipation from low fibre intake or dehydration all show up regularly.
The opioid patient is the case worth flagging separately. Opioids slow peristalsis directly, at the mu receptors in the gut, and they also increase water reabsorption from the colon. A stool softener alone treats neither mechanism. Standing orders for anyone on scheduled opioids should pair docusate with a stimulant such as senna, started prophylactically rather than waiting for constipation to develop, because opioid-induced constipation does not resolve on its own and tolerance to it does not build the way it does to sedation or nausea.
Assessment before administration
Check for the classic contraindications first: suspected bowel obstruction, undiagnosed abdominal pain, appendicitis, or active inflammatory bowel disease flare. A stimulant laxative given into an obstructed bowel risks perforation.
Review baseline bowel pattern, last bowel movement, and stool consistency using a description or the Bristol Stool Chart if your unit uses one. Assess hydration status, particularly before giving an osmotic agent, since these draw fluid into the bowel lumen and can worsen dehydration in a patient who is already fluid-depleted. Auscultate bowel sounds. Check renal function before magnesium-based products, since impaired renal clearance raises the risk of hypermagnesemia. For any patient on opioids, confirm whether a bowel regimen is already in place rather than starting from scratch.
Toxicity and the antidote
There is no specific antidote for laxative overuse; management is supportive and directed at the consequence, not the drug. Chronic stimulant laxative overuse produces a predictable pattern: hypokalemia, hyponatremia, and dehydration from repeated fluid and electrolyte loss, sometimes progressing to laxative dependence where the bowel loses its own contractile response and needs escalating doses to function.
Magnesium-containing osmotic laxatives, including magnesium hydroxide, carry a real risk of hypermagnesemia in patients with renal impairment, presenting as diminished deep tendon reflexes, hypotension, and respiratory depression as levels rise. Treatment is supportive: IV calcium gluconate to antagonise cardiac effects, IV fluids, and dialysis in severe renal failure. Electrolyte panels should be monitored in any patient on prolonged laxative therapy, not just after an overdose.
Interactions that matter
Mineral oil taken with docusate increases systemic absorption of the mineral oil, raising the risk of lipid pneumonia and systemic toxicity; the two should not be co-administered. Osmotic and stimulant laxatives can reduce absorption of concurrently administered oral medications by speeding transit time through the gut, so timing matters for narrow-therapeutic-index drugs.
Bulk-forming agents such as psyllium can bind and reduce absorption of other oral drugs if taken too close together; space doses by at least two hours. Chronic laxative-induced hypokalemia potentiates digoxin toxicity, so a patient on both needs closer potassium and digoxin level monitoring than either drug alone would warrant.
What the patient must be told
Explain which class they have been given and what it will actually do: a softener eases passage but will not create the urge to go, so if they are also constipated from opioids they need to know why a second medication is on the chart. Reinforce adequate fluid intake with any osmotic or bulk-forming agent, since these depend on water to work and can worsen constipation or cause obstruction without it.
Warn against long-term unsupervised use of stimulant laxatives, and explain that overuse can make the bowel dependent on the drug to function. Bulk-forming agents need to be taken with a full glass of water, never dry, because swelling in the oesophagus is a choking and obstruction risk. Tell patients to report cramping, rectal bleeding, or no bowel movement after 24 to 48 hours of use rather than doubling the dose themselves.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our pharmacology practice questions are the closest set to what this page covers.
One question from the pharmacology set
A client with heart failure is started on furosemide 40 mg PO daily. Which findings should the nurse report to the provider before administering the next dose? Select all that apply.
Rationale
Furosemide is a loop diuretic, so the two things you are watching are potassium and kidney function. A potassium of 2.9 mEq/L is below the 3.5–5.0 reference range and puts the client at risk for dysrhythmia — hold and report. Muscle cramps with palpitations are the clinical face of that same hypokalemia, so they are reported together, not separately. A creatinine that doubles signals the diuresis has outrun renal perfusion. A blood pressure of 132/78 and a 1 kg loss are the expected response to the drug working, not reasons to hold it.
Answer: A, D, E
Common questions
Is docusate a stimulant laxative?
No. Docusate is a stool softener that works as a surfactant, allowing water into the stool. It does not stimulate bowel motility, which is why it is not sufficient on its own for opioid-induced constipation.
Why are docusate and senna often prescribed together?
Docusate softens the stool while senna stimulates peristalsis to move it along. Opioids both slow motility and dry out stool, so treating only one mechanism leaves the other unaddressed.
Can you give a laxative if bowel sounds are absent?
Absent bowel sounds warrant further assessment before any laxative is given, since this can signal ileus or obstruction. Hold the dose and notify the provider rather than administering on schedule.
How quickly does polyethylene glycol work?
Onset is typically 1 to 3 days with standard daily dosing, or within a few hours when given in the larger volumes used for bowel prep. It works by osmosis, so adequate oral fluid intake supports its effect.
What electrolyte should you monitor with long-term laxative use?
Potassium. Chronic stimulant laxative use is a recognised cause of hypokalemia, and low potassium in turn increases the risk of digoxin toxicity and cardiac arrhythmia in susceptible patients.
More on pharmacology
Guides on this